Compound News and Research

RSS

Winners of the 2009 Biotechnology Vision Summit's Emerging Company Showcase announced

Six Wisconsin biotechnology companies have been selected the winners of the first Emerging Company Showcase. The showcase is part of the Biotechnology Vision Summit 2009, being held on Wednesday, Oct. 7, at the Madison Marriott West in Madison, Wis. The summit and the showcase are being hosted by BioForward, the member-driven state association that is the voice of Wisconsin’s biotechnology industry.

22 Sep 2009

Bayer's regorafenib showed 50% stabilization rate in RCC patients

Bayer today announced results from a Phase II trial of regorafenib (BAY 73-4506), a potent oral multi-kinase inhibitor, which demonstrated that treatment with regorafenib resulted in a 31 percent partial response rate and 50 percent stabilization rate in patients with metastatic renal cell carcinoma (RCC).

22 Sep 2009

Rexahn and Teva sign license and stock purchase agreements

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and central nervous system (CNS) therapeutics, today announced that it has closed on its previously announced licensing and stock purchase agreements with Teva Pharmaceutical Industries Limited, a top 20 pharmaceutical company, for the development of its novel anti-cancer compound, RX-3117. RX-3117 is a small molecule, new chemical entity (NCE), nucleoside compound that has an anti-metabolite mechanism of action, and has therapeutic potential in a broad range of cancers including colon, lung and pancreatic cancer.

22 Sep 2009

Investigative drug hampers the survival of non-Hodgkin lymphoma cells

An investigative drug deprived non-Hodgkin lymphoma cells of their ability to survive too long and multiply too fast, according to an early study published recently in the journal Experimental Hematology.

22 Sep 2009

Gene variant shows a strong gender bias for cancer predisposition

Cancer predisposition resulting from the presence of a specific gene variant shows a strong gender bias, researchers at the University of Cincinnati (UC) have demonstrated.

22 Sep 2009

Neurodegenerative disorders are the second-leading cause of early-onset dementia, says report

Neurodegenerative disorders called frontotemporal dementias (FTD) are the second-leading cause of early-onset dementia in persons under age 65 and can emerge sometimes as early as age 20.

21 Sep 2009

Enzo Biochem and NEI join to conduct a human clinical trial of Enzo’s chronic autoimmune uveitis therapeutic

Enzo Biochem, Inc. (NYSE: ENZ), announced today that it had entered into a Cooperative Research and Development Agreement (CRADA) with the National Eye Institute, part of the National Institute of Health, to conduct a human clinical trial of Optiquel™, Enzo’s oral, proprietary therapeutic for chronic autoimmune uveitis.

21 Sep 2009

Anavex completes manufacturing of Alzheimer's disease drug ANAVEX 2-73 for its clinical trials

Anavex Life Sciences Corp., ("ANAVEX") (OTCBB: AVXL) today announced the completion of scale-up manufacturing of ANAVEX 2-73, its lead compound for the treatment of Alzheimer's disease.

21 Sep 2009

Results of Phase 1 study of Oral AEZS-112 announced by Aeterna Zentaris

Æterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS) ("the Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced the completion of a Phase 1 study of its orally-active tubulin and topoisomerase II inhibitor compound, AEZS-112, in patients with advanced solid tumors or lymphoma, which may potentially provide a new therapeutic approach for the treatment of cancer.

21 Sep 2009

JANSSEN Alzheimer Immunotherapy acquires Elan

Johnson & Johnson and Elan Corporation plc today announced that JANSSEN Alzheimer Immunotherapy, a newly formed subsidiary of Johnson & Johnson, has completed the acquisition of substantially all of the assets and rights of Elan related to its Alzheimer's Immunotherapy Program (AIP).

18 Sep 2009

Metabolic Research to participate in the Olympia Expo

Metabolic Research, Inc., makers of Stemulite, will have a booth in the Olympia Expo at the Las Vegas Convention Center South Hall, September 25th and 26th. The Stemulite booth will feature Corey and Paul Simpson, well-known super athlete trainers joined by Cristi Cuellar, Miss Bikini Mexico International Elite Champion.

18 Sep 2009

Rexahn to sign licensing and stock purchase agreements with Teva Pharmaceutical

18 Sep 2009

Karo Bio receives US patent for its thyroid hormone receptor platform

The Swedish biotech company Karo Bio today announced that it has expanded and further strengthened the intellectual property portfolio for its thyroid hormone receptor (TR) platform by entering into an agreement that provides Karo Bio with an exclusive license to a US patent from Pfizer Inc.

18 Sep 2009

New tool developed to provide precise and cost-effective data collection for drug discovery efforts

Cancer and cell biology experts at the University of Cincinnati (UC) have developed a new mass spectrometry-based tool they say provides more precise, cost-effective data collection for drug discovery efforts.

18 Sep 2009

Results from Phase IIb clinical trial evaluating the safety and efficacy of GSK1838262/XP13512 announced

GlaxoSmithKline (NYSE:GSK) and XenoPort, Inc. (Nasdaq:XNPT) today announced top-line results from a Phase IIb clinical trial evaluating the safety and efficacy of GSK1838262/XP13512 (gabapentin enacarbil) for neuropathic pain associated with post-herpetic neuralgia (PHN) in adults.

17 Sep 2009

Electronic filing format to improve accuracy of registrations and drug listings

The U.S. Food and Drug Administration (FDA) now requires that establishment registration and drug listing information be filed in electronic format.

17 Sep 2009

New legislation protects healthcare coverage for rare disease clinical trial participants

Four members of the United States Senate introduced legislation today to allow patients with rare diseases to participate in clinical drug studies without losing their eligibility for public healthcare coverage, echoing a move by the House of Representatives last month.

17 Sep 2009

Bayer HealthCare to present its clinical trial data at a joint Multidisciplinary Congress

Bayer HealthCare today announced that data from more than 30 clinical trials evaluating three products in the company's oncology portfolio - Nexavar(R) (sorafenib) tablets, regorafenib (BAY 73-4506) and Alpharadin(TM) - will be presented at the joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress, September 20-24, 2009 in Berlin, Germany.

17 Sep 2009

Mechanism of action of the anti-cancer drug GMX1778 identified

Metabolon, Inc., the leader in metabolomics-driven biomarker discovery and analysis, today announced a new study has been published identifying the mechanism of action of the anti-cancer drug GMX1778. Co-authored by scientists at Gemin X Pharmaceuticals and Metabolon, the paper “The Small Molecule GMX1778 is a Potent Inhibitor of NAD+ Biosynthesis: Strategy for Enhanced Therapy in NAPRT1-Deficient Tumors” appears online ahead of print in Molecular and Cellular Biology.

17 Sep 2009

Findings may lead to drugs that destroy TB in dormant stage of lifecycle

Attempts to eradicate tuberculosis (TB) are stymied by the fact that the disease-causing bacteria have a sophisticated mechanism for surviving dormant in infected cells. Now, a team of scientists led by researchers from Weill Cornell Medical College has identified compounds that inhibit that mechanism -- without damaging human cells.

17 Sep 2009

Compound News and Research

Winners of the 2009 Biotechnology Vision Summit's Emerging Company Showcase announced

Bayer's regorafenib showed 50% stabilization rate in RCC patients

Rexahn and Teva sign license and stock purchase agreements

Investigative drug hampers the survival of non-Hodgkin lymphoma cells

Gene variant shows a strong gender bias for cancer predisposition

Neurodegenerative disorders are the second-leading cause of early-onset dementia, says report

Enzo Biochem and NEI join to conduct a human clinical trial of Enzo’s chronic autoimmune uveitis therapeutic

Anavex completes manufacturing of Alzheimer's disease drug ANAVEX 2-73 for its clinical trials

Results of Phase 1 study of Oral AEZS-112 announced by Aeterna Zentaris

JANSSEN Alzheimer Immunotherapy acquires Elan

Metabolic Research to participate in the Olympia Expo

Rexahn to sign licensing and stock purchase agreements with Teva Pharmaceutical

Karo Bio receives US patent for its thyroid hormone receptor platform

New tool developed to provide precise and cost-effective data collection for drug discovery efforts

Results from Phase IIb clinical trial evaluating the safety and efficacy of GSK1838262/XP13512 announced

Electronic filing format to improve accuracy of registrations and drug listings

New legislation protects healthcare coverage for rare disease clinical trial participants

Bayer HealthCare to present its clinical trial data at a joint Multidisciplinary Congress

Mechanism of action of the anti-cancer drug GMX1778 identified

Findings may lead to drugs that destroy TB in dormant stage of lifecycle

Enhancing confidence in chemical ionization spectrometry data eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News